Ning Wu

Ning Wu


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YMYue Ming
Yue Ming
NWNan Wu
Nan Wu
TQTianyi Qian
Tianyi Qian
XLXiao Li
Xiao Li
DWDavid Q. Wan
David Q. Wan
NWNing Wu
Ning Wu
Breast cancer is a major disease with high morbidity and mortality in women worldwide. Increased use of imaging biomarkers has been shown to add more information with clinical utility in the detection and evaluation of breast cancer. To date, numerous studies related to PET-based imaging in breast cancer have been published. Here, we review available studies on the clinical utility of different PET-based molecular imaging methods in breast cancer diagnosis, staging, distant-metastasis detection, therapeutic and prognostic prediction, and evaluation of therapeutic responses. For primary breast cancer, PET/MRI performed similarly to MRI but better than PET/CT. PET/CT and PET/MRI both have higher sensitivity than MRI in the detection of axillary and extra-axillary nodal metastases. For distant metastases, PET/CT has better performance in the detection of lung metastasis, while PET/MRI performs better in the liver and bone. Additionally, PET/CT is superior in terms of monitoring local recurrence. The progress in novel radiotracers and PET radiomics presents opportunities to reclassify tumors by combining their fine anatomical features with molecular characteristics and develop a beneficial pathway from bench to bedside to predict the treatment response and prognosis of breast cancer. However, further investigation is still needed before application of these modalities in clinical practice. In conclusion, PET-based imaging is not suitable for early-stage breast cancer, but it adds value in identifying regional nodal disease and distant metastases as an adjuvant to standard diagnostic imaging. Recent advances in imaging techniques would further widen the comprehensive and convergent applications of PET approaches in the clinical management of breast cancer.

1 February 2019 in Lung Cancer
Verified
Journal Article
Closed access
JSJufang Shi
Jufang Shi
LWLe Wang
Le Wang
NWNing Wu
Ning Wu
JLJun-Ling Li
Jun-Ling Li
ZHZhou-Guang Hui
Zhou-Guang Hui
MDMin Dai
Min Dai

4 September 2019 in European Radiology
Verified
Journal Article
Closed access
PDF file
LQLin-Lin Qi
Lin-Lin Qi
BWBo-Tong Wu
Bo-Tong Wu
WTWei Tang
Wei Tang
LZLi-Na Zhou
Li-Na Zhou
YHYao Huang
Yao Huang
JWJian-Wei Wang
Jian-Wei Wang

11 February 2020 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
XTXiuli Tao
Xiuli Tao
NLNing Li
Ning Li
NWNing Wu
Ning Wu
JHJie He
Jie He
JYJianming Ying
Jianming Ying
ZZZewei Zhang
Zewei Zhang
Purpose: Investigate whether 18F-FDG PET-CT has the potential to predict the major pathologic response (MPR) to neoadjuvant sintilimab in resectable NSCLC patients, and the potential of sifting patients who probably benefit from immunotherapy. Methods: Treatment-naive patients with resectable NSCLC (stage IA–IIIB) received two cycles of sintilimab (200 mg, intravenously, day 1 and 22). Surgery was performed between day 29 and 43. PET-CT was obtained at baseline and prior to surgery. The following lean body mass–corrected metabolic parameters were calculated by PET VCAR: SULmax, SULpeak, MTV, TLG, ΔSULmax%, ΔSULpeak%, ΔMTV%, ΔTLG%. PET responses were classified using PERCIST. The above metabolic information on FDG-PET was correlated with the surgical pathology. (Registration Number: ChiCTR-OIC-17013726). Results: Thirty-six patients received 2 doses of sintilimab, all of whom underwent PET-CT twice and had radical resection (35) or biopsy (1). MPR occurred in 13 of 36 resected tumors (36.1%, 13/36). The degree of pathological regression was positively correlated with SULmax (p = 0.036) of scan-1, and was negatively correlated with all metabolic parameters of scan-2, and the percentage changes of the metabolic parameters after neoadjuvant therapy (p < 0.05). According to PERCIST, 13 patients (36.1%, 13/36) showed partial metabolic response (PMR), 21 (58.3%, 21/36) had stable metabolic disease, and 2 (5.6%, 2/36) had progressive metabolic disease (PMD). There was a significant correlation between the pathological response and the PET responses which were classified using PERCIST. All (100.0%) the PMR (ΔSULpeak% < − 30.0%) tumors showed MPR. Conclusions: 18F-FDG PET-CT can predict MPR to neoadjuvant sintilimab in resectable non-small cell lung cancer.

4 October 2013 in BMC Neurology
Verified
Journal Article
Open access
PDF file
NANeetu Agashivala
Neetu Agashivala
NWNing Wu
Ning Wu
SASafiya Abouzaid
Safiya Abouzaid
YWYou Wu
You Wu
EKEdward Kim
Edward Kim
DBDavid W Brandes
David W Brandes
Adherence to disease-modifying therapies (DMTs) results in the reduction of the number and severity of relapses and delays the progression of multiple sclerosis (MS). Patients with lower adherence rates experience more inpatient visits and higher MS-related medical costs. Fingolimod, the first oral DMT approved by the US Food and Drug Administration, may improve the access and compliance to MS treatment when compared to injectable DMTs.

22 April 2015 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
SZShi‐Jun Zhao
Shi‐Jun Zhao
NWNing Wu
Ning Wu
Lung cancer is currently the leading cause of cancer‐related death in China and western countries for both men and women. Overall, the five‐year survival rate of lung cancer is approximately 15%, whereas the five‐year survival for patients with surgically resected early‐stage disease is 60–80%. Screening is conceptually a good strategy for reducing the mortality rate of lung cancer. Randomized controlled trials in the 1960s and 1970s found that chest radiographic screening did not result in a reduction in mortality for high‐risk individuals. Recently published data from the National Lung Screening Trial (NLST) showed a 20% reduction in lung cancer mortality in subjects who underwent low‐dose computed tomography (LDCT) screening compared to those randomized to conventional chest X‐ray. The encouraging results of the NLST, however, could not be confirmed by the preliminary results of ongoing European trials. More results from European randomized controlled trials are expected in the next few years. Recently, a number of lung cancer screening studies using LDCT have been initiated in China. This article briefly summarizes the results of the current and previous lung cancer screening trials worldwide, and focuses on the current status of LDCT lung cancer screening in China.